This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Adgero Biopharmaceuticals, Inc.

Drug Names(s): rostaporfin, PhotoPoint SnET2, SnET2-PDT, Photrex, REM-001 Therapy

Description: REM-001 is a photosensitizer that generates free-radicals when exposed to light energy. REM-001 Therapy is the collective name for a three-part photodynamic therapy that consists of a laser light source, a light delivery device and the drug REM-001.

Deal Structure: At an undisclosed time, Adgero Biopharmaceuticals acquired a portfolio of assets including REM-001 from Miravant Medical Technologies.

REM-001 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug